CN102114104A - New application of dittany bark extract in resisting atherosclerosis - Google Patents
New application of dittany bark extract in resisting atherosclerosis Download PDFInfo
- Publication number
- CN102114104A CN102114104A CN2010100001453A CN201010000145A CN102114104A CN 102114104 A CN102114104 A CN 102114104A CN 2010100001453 A CN2010100001453 A CN 2010100001453A CN 201010000145 A CN201010000145 A CN 201010000145A CN 102114104 A CN102114104 A CN 102114104A
- Authority
- CN
- China
- Prior art keywords
- disease
- atherosclerosis
- cortex dictamni
- extract
- bark extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses new application of a dittany bark extract in preventing and treating cardiovascular diseases, in particular preventing and treating atherosclerosis and coronary atherosclerotic heart disease (coronary disease) primarily caused by atherosclerosis. The dittany bark extract can resist oxidation and inhibit the formation of atheromatous plaque, has the advantages of little side effect, low cost and good druggability, and has good development prospect.
Description
Technical field the present invention relates to the extract prevention and the treatment cardiovascular disease of Cortex Dictamni (Cortex Dictamn), particularly prevent and treat atherosclerosis with and as the primary new purposes of the coronary atherosclerotic heart disease (coronary heart disease) of pathogenic factors.
Background technology is the improve of people's living standard at any time, the change of dietary structure and living habit, and the sick disease of painstaking effort becomes the No.1 disease of harm people life security.Wherein modal is to be the coronary heart disease of primary pathogenic factors with atherosclerosis, has had a strong impact on people's quality of life, therefore prevents and treats atherosclerosis and has very important significance.Research in the past thinks that atherosclerotic pathogenesis is " syndrome of blood stasis ", thereby blood-activating stasis-removing kind Chinese medicine is intervened atherosclerotic pathological changes a large amount of bibliographical informations is arranged, domestic Chinese patent medicine such as FUFANG DANSHEN PIAN, Radix Salviae Miltiorrhizae drop pill, Heart pill of Musk etc. have striden into the disappear ranks of the volume of selling of more than one hundred million units, but from clinically, the cause of the death that coronary heart disease caused is still high occupies the forefront, the method of preventing and treating that present Chinese and western drugs is described can't be removed the threat of atherosclerosis to people's life, need the research clinical efficacy good, the less original new drug of toxic and side effects could reduce the sickness rate and the case fatality rate of primary disease.Planted in that atherosclerosis is constantly furtherd investigate, antioxidant suppress that atheromatous plaque forms and more oversensitive angiopathy in application obtain paying attention to, this class medicine at the Chinese medicine extract tool with a large amount of resources.
Summary of the invention
The new purposes that Cortex Dictamni extract antioxidation that the invention discloses and atherosclerosis speckle form, invention process detailed process is achieved by pharmaceutical chemistry and pharmaceutical research.
It is as follows that Cortex Dictamni extract in the object of the invention possesses preparation method, dry Cortex Dictamni 100g, 4 ℃ of mercerations of 2L distilled water 24 hours, ultrasonic extraction 25min filters, triplicate, merge extractive liquid,, on Rotary Evaporators 80 ℃ concentrate extract 6.16g,-20 ℃ of preservations are faced and are used preceding distilled water diluting.
Detailed process of the present invention: antioxidation test comprises that polyphenol content measures, 1, and the mensuration (RP) of bitter diazanyl free radical (DPPH) the removing ability of 1-diphenyl-2-and total reducing power records that polyphenol content is 11.7 ± 0.52mg in every g Cortex Dictamni extract.And DPPH removing ability is compared with the positive control vitamin C with total also ability, has suitable oxidation resistance.Cortex Dictamni extract is to Cu simultaneously
2+Inductive human ldl (LDL) oxidation has tangible resistancing action.
Table 1 Cortex Dictamni is to Cu
2+The influence of inductive LDL oxidation susceptible (x ± s)
Annotate: * and matched group be P＜0.01 relatively; CD Cortex Dictamn Cortex Dictamni extract
With the Cortex Dictamni extract of high, normal, basic three dosage to the high Atherosclerosis Model ApoE-in 6 ages in week/-the mice administration, and give high age in fat load feedstuff to 12 week simultaneously, induce the formation of atherosclerotic lesion speckle.Each dosage group of Cortex Dictamni water extract all can significantly suppress atherosclerosis early lesion area, and matched group is no significant difference then.Quantitative analysis shows, the pathological changes area of matched group and Cortex Dictamni water extract senior middle school low dose group is respectively 9.79% ± 1.78%, 3.68% ± 1.56%, 3.86% ± 1.34%, 5.41% ± 0.96%, learn by statistics and handle, each administration group pathological changes area and matched group relatively have significant differences (P＜0.01).See that each administration group has the dose-effect positive correlation on the inhibition effect to the atheromatous plaque generation.
Experimental result shows, Cortex Dictamni extract has antioxidation, and can suppress ApoE-/-generation of mice atheromatous plaque, the present invention is specially adapted to the cardiovascular disease that can prevent and treat by antioxidation, is specially adapted to prevent and treat atheromatosis.
The specific embodiment
1 dry Cortex Dictamni 100g, 4 ℃ of mercerations of 2L distilled water 24 hours, ultrasonic extraction 25min filter, triplicate, merge extractive liquid,, on Rotary Evaporators 80 ℃ concentrate extract 6.16g, each dosage contains extract 6g, once-a-day.
2 dry Cortex Dictamni 200g, 4 ℃ of mercerations of 2L distilled water 24 hours, ultrasonic extraction 25min filter, triplicate, merge extractive liquid,, on Rotary Evaporators 80 ℃ concentrate extract 11.79g, each dosage contains extract 3g, a twice-daily.
Claims (5)
1. Cortex Dictamni extract is used for preventing and treating the application of the medicine of cardiovascular disease in preparation.
2. according to the purposes of claims 1, cardiovascular disease wherein comprise can be by prevention of antioxidation approach and treatment indication disease, particularly atherosclerosis with and as the primary coronary atherosclerotic heart disease of pathogenic factors.
3. according to the purposes of claims 1, the application process of prevention and treatment cardiovascular disease comprises that the Cortex Dictamni extract with effective dose is the pharmaceutical composition of composition.
4. according to the purposes of claims 1, the application process of prevention and treatment cardiovascular disease comprises the pharmaceutical preparation made from the Cortex Dictamni extract of effective dose, and dosage form comprises all dosage forms on the pharmaceutics.
5. according to the method for claims 3 or 4, cardiovascular disease wherein comprise can be by prevention of antioxidation approach and treatment indication disease, particularly atherosclerosis with and as the primary coronary atherosclerotic heart disease of pathogenic factors.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010100001453A CN102114104A (en) | 2010-01-06 | 2010-01-06 | New application of dittany bark extract in resisting atherosclerosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010100001453A CN102114104A (en) | 2010-01-06 | 2010-01-06 | New application of dittany bark extract in resisting atherosclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102114104A true CN102114104A (en) | 2011-07-06 |
Family
ID=44213104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010100001453A Pending CN102114104A (en) | 2010-01-06 | 2010-01-06 | New application of dittany bark extract in resisting atherosclerosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102114104A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113679765A (en) * | 2021-09-30 | 2021-11-23 | 上海家化联合股份有限公司 | Cortex dictamni extract and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101543546A (en) * | 2008-03-28 | 2009-09-30 | 上海安普生物科技有限公司 | Antioxidative substance and composition and use thereof |
-
2010
- 2010-01-06 CN CN2010100001453A patent/CN102114104A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101543546A (en) * | 2008-03-28 | 2009-09-30 | 上海安普生物科技有限公司 | Antioxidative substance and composition and use thereof |
Non-Patent Citations (1)
| Title |
|---|
| 杨永宗主编: "《动脉粥样硬化病心血管病基础与临床》", 31 July 2009, 科学出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113679765A (en) * | 2021-09-30 | 2021-11-23 | 上海家化联合股份有限公司 | Cortex dictamni extract and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sayyah et al. | Comparison of Silybum marianum (L.) Gaertn. with fluoxetine in the treatment of Obsessive− Compulsive Disorder | |
| Zaid et al. | Greco-Arab and Islamic herbal-derived anticancer modalities: From tradition to molecular mechanisms | |
| Brenyo et al. | Review of complementary and alternative medical treatment of arrhythmias | |
| Almatar et al. | A glance on medical applications of Orthosiphon stamineus and some of its oxidative compounds | |
| CN105477380A (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases and preparation method of traditional Chinese medicine | |
| Datta | High-Diluted-Potential-Internal-Biomedicines Zingiber officinale Extract Prevent 21st-Century Pandemic: En-riched Drugs Health Socio-Economy | |
| US9211310B2 (en) | Use of a Chinese medicine composition in preparing medicaments for treating secondary prevention of myocardial infarction | |
| CN102697982B (en) | Composition having auxiliary blood fat reducing effect and preparation method thereof | |
| Bi et al. | Preventive effect of different citrus essential oils on primary dysmenorrhea: in vivo and in vitro study | |
| Frieri | Herbal therapies: what allergist-immunologists should know regarding patient use of complementary and alternative medicine | |
| CN102631525B (en) | Health care product with function of blood pressure reduction and preparation method thereof | |
| CN102772611B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| KR102169673B1 (en) | Composition for preventing, improving or treating stress diseases comprising Platycodi Radix extract | |
| CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
| CN102114104A (en) | New application of dittany bark extract in resisting atherosclerosis | |
| Adepoju et al. | Evaluation of the effect of lime fruit juice on the anticoagulant effect of warfarin | |
| JP2019501912A (en) | Use of citrus extract and isoacteoside in muscle protection | |
| CN108619358A (en) | The new application of pharmaceutical composition | |
| Oguwike et al. | Evaluation of efficacy of walnut (Juglans Nigra) on blood pressure, haematological and biochemical profile of hypertensive subjects | |
| CN105596889A (en) | Antitumor composition containing resveratrol and preparation method of antitumor composition | |
| CN105194352B (en) | A kind of Chinese medicine composition and preparation method thereof improving learning and memory | |
| CN110463799A (en) | A kind of wild plant composition of protect liver constipation-relieving tea | |
| CN107007717A (en) | A kind of pharmaceutical composition for treating stomachache syndrome of incoordination between liver and stomach | |
| US20240115590A1 (en) | Compositions and therapeutic methods for treating chronic sequalae following viral infections | |
| JP5950493B2 (en) | Fatigue recovery agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110706 |